The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells

Leukemia Research

Volumn 27, Issue 1, 2003, Pages 79-84

  Ramage, Jason G ^a   Vallera, Daniel A ^b   Black, Jennifer H ^a   Aplan, Peter D ^c   Kees, Ursula R ^d   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Acute myeloid leukemia; Diphtheria fusion protein; Urokinase receptor

Indexed keywords

DIPHTHERIA TOXIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PHYCOERYTHRIN; PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CATALYSIS; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN U937; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAJI CELL;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; BLAST CRISIS; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; JURKAT CELLS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, T-CELL, ACUTE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; TUMOR STEM CELLS; U937 CELLS;

EID: 0037212018     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00077-2     Document Type: Article

References (51)

1. Stone R.M., Berg D.T., George S.L., Dodge R.K., Paciucci P.A., Schulman P.P.et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 98:2001;548.
2. Estey E.H. How I treat older patients with AML. Blood. 96:2000;1670.
3. Feuring-Buske M., Frankel A.E., Gerhard B., Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol. 28:2000;1390.
4. Alexander R.L., Ramage J., Kucera G.L., Caligiuri M.A., Frankel A.E. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 25:2001;875.
5. Ploug M., Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. FEBS Lett. 349:1994;163.
6. Fazioli F., Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmcol Sci. 15:1994;25.
7. Preissner K.T., Kanse S.M., May A.E. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 12:2000;621.
8. Jardi M., Ingles-Esteve J., Burgal M., Azqueta C., Velasco F., Lopez-Pedrera C., Miles L.A., Felez J. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thrombosis Haemostasis. 76:1996;1009.
9. Nykjaer A., Moller B., Todd R.F., Christensen T., Andreasen P.A., Gliemann J., Petersen C.M. Urokinase receptor: an activation antigen in human T lymphocytes. J Immunol. 152:1994;505.
10. Lanza F., Castoldi G.L., Castagnari B., Todd R.F., Moretti S., Spisani S.et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol. 103:1998;110.
11. Sillaber C., Baghestanian M., Hofbauer R., Virgolini I., Bankl H.C., Fureder W.et al. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 272:1997;7824.
12. Miles L.A., Plow E.F. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thrombosis Haemostasis. 58:1987;936.
13. Plesner T., Ralfklaer E., Wittrup M., Johnsen H., Pyke C., Pedersen T.L.et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 102:1994;835.
14. Kroon M.E., Koolwijk P., van der Vecht B., van Hinsbergh V.W.M. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood. 96:2000;2775.
15. Haddock R.C., Spell M.L., Baker C.D., Grammer R., Parks J.M., Speidel M.et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 266:1991;21466.
16. Plow E.F., Freaney D.E., Plescia J., Miles L.A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 103:1986;2411.
17. Blasi F., Stoppelli M.P., Cubellis M.V. The receptor for urokinase-plasminogen activator. J Cell Biochem. 32:1986;179.
18. Ragno P., Montuori N., Covelli B., Hoyer-Hansen G., Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen activator receptor in normal and tumor thyroid cells. Cancer Res. 58:1998;1315.
19. Wohn K.D., Kanse S.M., Deutsch V., Schmidt T., Eldor A., Preissner K.T. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thrombosis Haemostasis. 77:1997;540.
20. M'Liss A., Hudson L., McReynolds L.M. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. JNCI. 89:1997;709.
21. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J.S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53:1993;4143.
22. Ploug M., Ostergaard S., Gardsvoll H., Kovalski K., Holst-Hansen C., Holm A., Ossowski L., Dano K. Peptide-derived antagonists of the urokinase receptor. Biochemistry. 40:2001;12157.
23. Ippoliti R., Lendaro E., Benedetti P.A., Torrisi M.R., Belleudi F., Carpani D.et al. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J. 14:2000;1335.
24. 2-macroglobulin receptor. J Biol Chem. 275:2000;7566.
25. Engelholm L.H., Nielsen B.S., Netzel-Arnett S., Solberg H., Chen X.D., Garcia J.M.L.et al. The urokinase plasminogen activator receptor-associated protein/Endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab Invest. 81:2001;1403.
26. Vallera DA, Li C., Panoskaltsis-Mortari A, Hall WA, Targeting Overexpressed Urokinase-Type Plasminogen Activator Receptor (uPAR) on Human Glioblastoma with the Diphtheria Toxin Fusion Protein DTAT in Nude Mice, JNCI, (in press).
27. Tanabe S., Zeleznik-Le N.J., Kobayashi H., Vignon C., Espinosa R., LeBeau M.M., Thirman M.J., Rowley J.D. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer. 15:1996;206.
28. Strout M.P., Mrozek K., Heinonen K., Sait S.N.J., Shows T.B., Aplan P.D. ML-1 cell line lacks a germline MLL locus. Genes Chromosomes Cancer. 16:1996;204.
29. Kees U.R., Campbell L.J., Ford J., Willoughby M.L.N., Peroni S.E., Ranford P.R., Garson O.M. New translocation t(2;13)(p12;q34) and rearrangement of the MLL gene in a childhood leukemia cell line. Genes Chromosomes Cancer. 12:1995;201.
30. Gill Super H.J., Martinez-Climent J., Rowley J.D. Molecular analysis of the Mono Mac 6 cell line: detection of an MLL-AF9 fusion transcript. Blood. 85:1995;855.
31. Steube K.G., Teepe D., Meyer C., Zaborski M., Drexler H.G. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk Res. 21:1997;327.
32. Walter R., Schoedon G., Bachli E., Betts D.R., Hossle J.P., Calandra T., Joller-Jemelka H.I., Fehr J., Schaffner A. Establishment and characterisation of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). Br J Haematol. 109:2000;396.
33. Odero M.D., Zeleznik-Le N.J., Chinwalla V., Rowley J.D. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation. Genes Chromosomes Cancer. 29:2000;333.
34. 3 in nude mice bearing transplantable human myelogenous leukemic cell lines. Exp Hematol. 13:1985;722.
35. Ohyashiki K., Ohyashiki J.H., Kinniburgh A.J., Rowe J., Miller K.B., Raza A.et al. Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philiadelphia translocations. Cancer Genet Cytogenet. 26:1987;105.
36. Volpi E.V., Vatcheva R., Labella T., Gan S.U. More detailed characterization of some of the HL60 karyotypic features by fluorescence in situ hybridization. Cancer Genet Cytogenet. 87:1996;103.
37. Jiang J.D., Wang Y., Janish C.A., Holland J.F., Bekesi J.G. 3-bromoacetylamino benzyolurea (3-BAABU), a new antimicrotubule cancericidal agent applied in cytogenetic analysis in hematology. Biomed Pharmacother. 52:1998;270.
38. Kiser M., McCubrey J.A., Steelman L.S., Shelton J.G., Ramage J., Alexander R.L.et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 15:2001;814.
39. Weiss A., Wiskocil R.L., Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pre-translational level. J Immunol. 133:1984;123.
40. Yoshida M.C., Kodama Y. Karyological characterization of a human lymphoblastoid cell line resistant to 6-thioguanine. Hum Genet. 35:1977;201.
41. Shou Y., Martelli M.L., Gabrea A., Qi Y., Brents L.A., Roschke A.et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U.S.A. 97:2000;228.
42. Falnes P.O., Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 12:2000;407.
43. Nykjaer A., Christensen E.I., Vorum H., Hager H., Petersen C.M., Roigaard H.et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 141:1998;815.
44. Cavallaro U., del Vecchio A., Lappi D.A., Soria M.R. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem. 268:1993;23186.
45. Fabbrini M.S., Carpani D., Soria M.R., Ceriotti A. Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J. 14:2000;391.
46. Drexler H.G., Zaborski M., Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 11:1997;701.
47. Chen P., Chiu C., Chiou T., Maeda S., Chiang H., Tzeng C., Sugiyama T., Chiang B.N. Establishment and characterization of a human monocytoid leukemia cellline CTV-1. Gann. 75:1984;660.
48. Wang C., Curtis J.E., Minden M.D., McCulloch E.A. Expression of a retinoid acid receptor gene in myeloid leukemia cells. Leukemia. 3:1989;264.
49. Koeffler H.P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 62:1983;709.
50. Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 77:1991;2031.
51. Minowada, J., Immunology of leukemic cells. In: Gunz, F, Henderson, E, editors. Leukemia. Orlando (FL, USA): Grune & Stratton, 1982. p. 119.